What’s New with GBI Research's Premium Reports under the Pharmaceuticals Industry03 Nov 2011 • by Natalie Aster
Market Publishers Ltd informs that new GBI Research's Clean Pharmaceuticals Industry report has been added to its catalogue:
The anti-inflammatory therapeutics market is linked to seven diseases as major indications, which include respiratory inflammatory diseases (asthma and chronic obstructive pulmonary disease), arthritis (rheumatoid arthritis and osteoarthritis), multiple sclerosis, psoriasis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), spondyloarthropathies (ankylosing spondylitis and psoriatic arthritis), gout, and others (which includes the anti-inflammatory therapeutics market other than the seven major indications). The anti-inflammatory therapeutics market accounts for a share of 7.4% from global pharmaceutical revenues, and is expected to grow during the forecast period of seven years. The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications. From 2002, the market grew at a rate of 7.6% to $57..8 billion in 2010, and is forecast to grow at a rate of 5.8% during the forecast period, to produce revenues of $85.9 billion in 2017. This decrease from 7.6% to 5.8% will be due to patent expiries of some biologics and small molecules; these patent expiries will make an entry point for generics in the market, and their negative impact will be reversed by strong pipeline molecules that are currently in various phases of clinical trials.
The global neurodegenerative therapeutics market is valued as $16,828m in 2010, and grew from $11,055m in 2002 with a Compound Annual Growth Rate (CAGR) of 5.4%. An increase in the geriatric population globally, along with an increase in life expectancy, is expected to increase the disease population of neurodegenerative diseases. The product pipeline for neurodegenerative disease therapeutics is promising, with many novel molecules with disease modifying characteristics at various stages of clinical development, and these are expected to fulfill the unmet needs in the Neurodegenerative Disease Market. The product pipeline for multiple sclerosis has many orally administered novel molecules, while the Alzheimer’s disease therapeutic pipeline has novel molecules such as bapineuzumab, solanezumab, and BMS-708163, which target the underlying causes of the disease and thus may offer significant benefits to patients. The product pipeline also has promising molecules for rare disorders such as Huntington’s disease and amyotrophic lateral sclerosis and had shown better safety and efficacy profiles in clinical development. Although in the coming years the market will witness the patent expiries of major drugs, the rapid uptake of new molecules will stabilize the market decline and the market is expected to grow with a CAGR of 5.9% from 2010 to 2017 to reach $25,118m in 2017.
Report Price: $3.500.00 (Single User License)
More new market research reports by GBI Research can be found at publisher page.
To order the report or ask for sample pages contact email@example.com